Melanoma Coverage from Every Angle
Advertisement
Advertisement

Plasma Levels of TKL-40 Glycoprotein: Prognostic Biomarker in Melanoma?

By: Cordi Craig
Posted: Monday, November 18, 2019

Measured increasing plasma YKL-40 levels appear to be associated with reduced survival in patients with melanoma; however, YKL-40 is unlikely a causal factor of the disease because genetically predicted high plasma YKL-40 levels did not appear to be associated with survival. Stig E. Bogesen, MD, PhD, DMSci, of the University of Copenhagen, and colleagues propose that plasma YKL-40 levels are correlated with mortality but not a causal factor. The report was published in the European Journal of Cancer

To test whether measured and genetically predicted high plasma levels of YKL-40—a secretory glycoprotein associated with inflammation and tissue remodeling—were associated with increased mortality, the investigators studied two cohorts with a total of 4,031 patients with melanoma: 2,618 patients from hospital clinics and 1,413 general population patients. The researchers tested all patients for CHI3L1 rs4950928, a gene that is highly predictive of lifelong plasma YKL-40 levels, and measured plasma YKL-40 levels in 2,165 patients.

Age- and sex-adjusted hazard ratios for death among patients in the hospital melanoma cohort with measured plasma YKL-40 levels in the 96th to 100th percentile were 1.52 versus 1.07 in the 1st to 95th percentile and per 10-percentile increases. The effects were most pronounced among patients with localized melanomas. 

The C allele of the CHI3L1 rs4950928 genotype was associated with increasing plasma YKL-40 levels in 32% of patients in the hospital cohort and 43% of the general population cohort (P < .0001). Among the combined cohorts, the multifactorial adjusted ratios for the increases were 1.04 and 0.98 for measured and genetically predicted plasma YKL-40 levels, respectively.

“Thus, our results indicate that measured increasing plasma YKL-40 is a marker and less likely to be a cause of increased mortality in patients with melanoma. These are novel findings,” the study authors concluded.

Disclosure: The study authors reported no conflicts of interest.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.